Evidence map›Paper›PMID 28711472›Full record

Trial reportSchizophrenia research2018

Interactive effects of an N-methyl-d-aspartate receptor antagonist and a nicotinic acetylcholine receptor agonist on mismatch negativity: Implications for schizophrenia.

Holly K Hamilton, Deepak C D'Souza, Judith M Ford, Brian J Roach, Naomi S Kort, Kyung-Heup Ahn, Savita Bhakta, Mohini Ranganathan, Daniel H Mathalon

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Schizophrenia research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 47 citations in OpenAlex.

  1. Trial
  2. Trial
  3. One-day tropisetron treatment improves cognitive deficits and P50 inhibition deficits in schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Holly K HamiltonSan Francisco VA Health Care System, 4150 Clement St 116D, San Francisco, CA 94121, USA; University of California, San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, USA.
Deepak C D'SouzaVeterans Affairs Connecticut Health Care System, 950 Campbell Ave, 116A, West Haven, CT 06516, USA; Yale University, 300 George St, Suite 901, New Haven, CT 06511, USA.
Judith M FordSan Francisco VA Health Care System, 4150 Clement St 116D, San Francisco, CA 94121, USA; University of California, San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, USA.
Brian J RoachNorthern California Institute for Research and Education, 4150 Clement St, San Francisco, CA 94121, USA.
Naomi S KortUniversity of California, San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, USA.
Kyung-Heup AhnVeterans Affairs Connecticut Health Care System, 950 Campbell Ave, 116A, West Haven, CT 06516, USA; Yale University, 300 George St, Suite 901, New Haven, CT 06511, USA.
Savita BhaktaYale University, 300 George St, Suite 901, New Haven, CT 06511, USA; Now at University of California, San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA.
Mohini RanganathanYale University, 300 George St, Suite 901, New Haven, CT 06511, USA.
Daniel H MathalonSan Francisco VA Health Care System, 4150 Clement St 116D, San Francisco, CA 94121, USA; University of California, San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, USA. Electronic address: daniel.mathalon@ucsf.edu.
Yale University · USUniversity of California, San Francisco · USNorthern California Institute for Research and Education · USSan Francisco VA Health Care System · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Predictive Coding Abnormalities in Psychosis: EEG and fMRIR01MH058262 · NIMH · YALE UNIVERSITY · PI FORD, JUDITH M · 1998 to 2018
$6.4M
Functional Brain Abnormalities in the Schizophrenia ProdromeR01MH076989 · NIMH · YALE UNIVERSITY · PI MATHALON, DANIEL H · 2007 to 2014
$2.3M
Neurobiological Mechanisms Underlying the Symptoms and Course of SchizophreniaT32MH089920 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FORD, JUDITH M · 2010 to 2014
$1.3M
NCATS NIH HHS UL1 TR001863NIMH NIH HHS R01 MH058262NIMH NIH HHS R01 MH076989NIMH NIH HHS T32 MH089920
6 · The paper itself

Abstract

N-methyl-d-aspartate glutamate receptor (NMDAR) hypofunction has been implicated in the pathophysiology of schizophrenia, including auditory processing abnormalities reflected by the mismatch negativity (MMN) event-related potential component. Evidence suggesting cognitive benefits from nicotine administration, together with the high rate of cigarette use in patients with schizophrenia, has stimulated interest in whether nicotine modulates NMDAR hypofunction. We examined the interactive effects of ketamine, an NMDAR antagonist that produces transient schizophrenia-like neurophysiological effects, and nicotine, a nicotinic acetylcholine receptor (nAChR) agonist, in 30 healthy volunteers to determine whether nicotine prevents or attenuates MMN abnormalities. Secondary analyses compared the profile of ketamine and schizophrenia effects on MMN using previously reported data from 24 schizophrenia patients (Hay et al. 2015). Healthy volunteers completed four test days, during which they received ketamine/placebo and nicotine/placebo in a double-blind, counterbalanced design. MMN to intensity, frequency, duration, and frequency+duration double deviant sounds was assessed each day. Ketamine decreased intensity, frequency, and double deviant MMN amplitudes, whereas nicotine increased intensity and double deviant MMN amplitudes. A ketamine×nicotine interaction indicated, however, that nicotine failed to attenuate the decrease in MMN associated with ketamine. Although the present dose of ketamine produced smaller decrements in MMN than those associated with schizophrenia, the profile of effects across deviant types did not differ between ketamine and schizophrenia. Results suggest that while ketamine and schizophrenia produce similar profiles of MMN effects across deviant types, nicotinic agonists may have limited potential to improve these putative NMDAR hypofunction-mediated impairments in schizophrenia.

Indexed as

AdolescentAdultAnalysis of VarianceAntipsychotic AgentsContingent Negative VariationCross-Over StudiesDouble-Blind MethodDrug InteractionsElectroencephalographyEvoked Potentials, AuditoryFemaleHealthy VolunteersHumansKetamineMaleNicotinic AgonistsAntipsychotic AgentsKetamineNicotinic AgonistsElectroencephalographyKetamineMismatch negativityNicotineNMDAR hypofunctionSchizophrenia

Identifiers

PMID28711472
PMCPMC5745273
OpenAlexW2735961249

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.